Nov 5 (Reuters) - AstraZeneca, the British drugmaker
working on one of the world's leading COVID-19 vaccine
candidates, on Thursday beat third-quarter sales estimates on
strong demand for its diverse portfolio of drugs during COVID-19
pandemic lockdowns and maintained its 2020 forecasts.
(Reporting by Pushkala Aripaka, Ludwig Burger in Frankfurt;
Editing by Bernard Orr)